Answers are grounded in this paper and cite their sources.
Parkinson’s disease is increasing in incidence at a faster rate than any other serious neurologic condition.1 Despite multiple agents putatively showing preclinical promise, there is no disease-modifying therapy available for clinical use in this disorder. Indeed, no potential treatment has survived scrutiny in a clinical trial to reach approval by a regulatory body. Several target mechanisms have been identified by which to achieve neuroprotection or neurorestoration of dopaminergic neurons that are at the nexus of Parkinson’s disease. One approach, which engendered much hope, has been the targeting of the pathologically aggregated form of the protein α-synuclein.2 Studies of active immunotherapy . . .
No takes yet. Share an insight, caveat, or question.
Alan L. Whone (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: